TrialPath
High blood pressure · Philadelphia

High blood pressure clinical trials in Philadelphia

20 recruiting hypertension studies within range of Philadelphia. Click any trial for full eligibility criteria and contact info.

Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

Recruiting

A multicenter randomized trial that will compare the effectiveness of two postpartum blood pressure (BP) management strategies in improving blood pressure and cardiac function and increasing patient engagement and feeling of control over one's health

PhaseNA
TypeInterventional
Age18 Years
WhereNew York, New York, United States + 2 more
SponsorJennifer Lewey, MD, MPH
▾Tap for details
Apply

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109 · High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Recruiting

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 1225 more
SponsorAlnylam Pharmaceuticals
▾Tap for details
Apply

Advanced Neuroimaging in Idiopathic Intracranial Hypertension

NCT06950099 · Idiopathic Intracranial Hypertension (IIH), Glymphatic System
Recruiting

Idiopathic intracranial hypertension (IIH) is characterized by elevated intracranial pressure leading to symptoms like papilledema, headache, and cognitive dysfunction. While the etiology is complex, abnormal cerebrospinal fluid dynamics due to venous outflow restriction from transverse sinus stenosis (TSS) is common. TSS may disrupt the glymphatic system, a brain-wide network facilitating cerebrospinal fluid and interstitial fluid exchange, by impairing CSF absorption, altering perivascular space dynamics, and disrupting pressure gradients crucial for waste clearance. Venous sinus stenting (VSS) can improve symptoms in many patients by alleviating venous congestion, but its effects on glymphatic function are unclear. This prospective study aims to evaluate novel quantitative brain imaging metrics as surrogate markers to better understand IIH pathophysiology before and after VSS in patients with refractory IIH and TSS. The investigators will use advanced MRI techniques, including MR elastography (MRE) to assess brain stiffness, diffusion tensor imaging (DTI) to evaluate water diffusion, arterial spin labeling (ASL) imaging to measure blood-brain barrier (BBB) permeability, and functional MRI to analyze pain networks. The investigators hypothesize that 1) these noninvasive imaging metrics will correlate with the degree of venous congestion and changes after venous sinus stenting (VSS) and 2) the imaging findings will correlate with clinical treatment outcomes. By correlating imaging markers with venous pressures and symptom changes, the investigators aim to gain insights into IIH mechanisms, expand diagnostic tools, and potentially guide clinical decision-making and treatment response monitoring. The overarching goal is to better understand IIH's underlying pathophysiology, which could lead to improved diagnostic criteria, more targeted treatments, and better prediction of treatment outcomes for patients with this challenging condition.

Phase—
TypeObservational
Age18 Years – 55 Years
WherePhiladelphia, Pennsylvania, United States
SponsorThomas Jefferson University
▾Tap for details
Apply

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

NCT02249923 · Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Recruiting

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

Phase—
TypeObservational
Age1 Day – 21 Years
WherePalo Alto, California, United States + 13 more
SponsorNew York Medical College
▾Tap for details
Apply

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Recruiting

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 1141 more
SponsorBoehringer Ingelheim
▾Tap for details
Apply

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

NCT07220876 · Open Angle Glaucoma (OAG)
Recruiting

A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial

PhaseNA
TypeInterventional
Age45 Years
WhereGlendale, Arizona, United States + 13 more
SponsorAvisi Technologies Inc.
▾Tap for details
Apply

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

NCT05470205 · Liver Diseases, Portal Hypertension
Recruiting

This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE (subharmonic aided pressure estimation) procedures using different ultrasound contrast agents (Definity \[Lantheus Medical Imaging, N Bilerica, MA, USA\] and Sonazoid \[GE Healthcare, Oslo, Norway\] in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare, Waukesha, WI, USA) and determine the reproducibility of the SHAPE algorithm. Cohort 2: Patients identified as having clinically significant portal hypertension (CSPH) will be monitored by SHAPE with Sonazoid for the duration of this project (18-24 months on average). These subjects will have follow-up ultrasound scans every 6 ± 2 months to check for hepatocellular carcinoma (HCC) (using the Barcelona-Liver Cancer staging system) as well as ascites and at those times a repeat SHAPE examination will be performed. Liver stiffness values will be measured with elastography as well. This cohort will examine if serial SHAPE can accurately predict development of ascites and other liver related events in patients with compensated cirrhosis undergoing routine HCC surveillance in a multi-center setting. Cohort 3: Subjects newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE and results compared to elastography measurements of liver stiffness with standard assessments (e.g., serum liver function tests and measurement of spleen size as well as platelet count). This cohort will establish if SHAPE can be used to monitor treatment response in patients identified with portal hypertension. Cohort 4: Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices relative to the Baveno VI and the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index will undergo a SHAPE examination. This cohort will compare the predictive ability of SHAPE for allocating patients with compensated advanced chronic liver disease to screening of varices compared to the current standard of care.

PhasePhase 3
TypeInterventional
Age18 Years
WherePhiladelphia, Pennsylvania, United States + 2 more
SponsorThomas Jefferson University
▾Tap for details
Apply

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891 · Hypertension
Recruiting

The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with uncontrolled hypertension (HTN) receiving 0 - 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving 1 - 2 anti-hypertensive drugs of different classes and who accept to be off-medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after the procedure

PhaseNA
TypeInterventional
Age22 Years – 75 Years
WhereBirmingham, Alabama, United States + 50 more
SponsorSoniVie Inc.
▾Tap for details
Apply

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802 · Atherosclerosis, Cardiovascular Disease, Obesity
Recruiting

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

PhasePhase 2
TypeInterventional
Age18 Years
WhereHuntsville, Alabama, United States + 45 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Recruiting

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereFresno, California, United States + 119 more
SponsorGossamer Bio USA, Inc.
▾Tap for details
Apply

Sleep Promotion and Pediatric Hypertension

NCT06642246 · Insufficient Sleep, Hypertension
Recruiting

Determine the effectiveness and feasibility of a mobile health sleep extension approach in the pediatric nephrology setting, to increase sleep duration and reduce systolic and diastolic blood pressure.

PhaseNA
TypeInterventional
Age13 Years – 18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorChildren's Hospital of Philadelphia
▾Tap for details
Apply

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

NCT07132788 · Pulmonary Hypertension
Recruiting

Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH. Subjects will be asked to attend a baseline visit where the following will be performed: * Measure your vital signs * Undergo a research blood draw, less than 4 tablespoons * Provide a urine pregnancy test (if applicable) * Review demographics, personal history, and medical history * Review current PAH medications * Complete questionnaires on how your PAH affects you * Complete a test of physical performance * Complete a grip strength test * Undergo an echocardiogram (Echo) * Complete a six-minute walk test * Undergo a Chest CT Scan * Undergo a scan of your body composition (DXA scan) * Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months

Phase—
TypeObservational
Age18 Years
WherePhiladelphia, Pennsylvania, United States + 1 more
SponsorUniversity of Pennsylvania
▾Tap for details
Apply

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195 · Heart Failure, Heart Diseases, Cardiovascular Diseases
Recruiting

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 69 more
SponsorAbbott Medical Devices
▾Tap for details
Apply

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

NCT06408181 · Pre-Eclampsia, Pregnancy Loss
Recruiting

The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.

PhasePhase 3
TypeInterventional
Age18 Years – 45 Years
WherePhiladelphia, Pennsylvania, United States
SponsorUniversity of Pennsylvania
▾Tap for details
Apply

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Recruiting

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 24 more
SponsorAllRock Bio, Inc.
▾Tap for details

Penn Medicine Healthy Heart

NCT06062394 · Hypertension, Hyperlipidemias
Recruiting

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

PhaseNA
TypeInterventional
Age35 Years – 80 Years
WherePhiladelphia, Pennsylvania, United States
SponsorUniversity of Pennsylvania
▾Tap for details
Apply

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).

PhasePhase 2
TypeInterventional
Age18 Years – 85 Years
WhereTucson, Arizona, United States + 3 more
SponsorIRulya Therapeutics Inc.
▾Tap for details
Apply

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221 · Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Recruiting

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

PhasePhase 4
TypeInterventional
Age18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorJonathon Myers
▾Tap for details
Apply

Novel Glaucoma Diagnostics

NCT00286637 · Glaucoma, Macular Disease
Recruiting

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Phase—
TypeObservational
Age18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorWills Eye
▾Tap for details
Apply

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06911632 · Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Recruiting

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

PhaseNA
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 40 more
SponsorTempus AI
▾Tap for details
Apply